Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach

Cell

Volumn 125, Issue 7, 2006, Pages 1253-1267

  Zender, Lars ^a   Spector, Mona S ^a   Xue, Wen ^a   Flemming, Peer ^b   Cordon Cardo, Carlos ^c   Silke, John ^d   Fan, Sheung Tat ^e   Luk, John M ^e   Wigler, Michael ^a   Hannon, Gregory J ^a,f   Mu, David ^a   Lucito, Robert ^a   Powers, Scott ^a   Lowe, Scott W ^a,f  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YAP; UNCLASSIFIED DRUG;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENETICS; CANCER MODEL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME 11Q; CHROMOSOME 9Q; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENOME ANALYSIS; GENOMICS; LIVER CANCER; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; STEM CELL; VALIDATION PROCESS;

EID: 33745253109     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2006.05.030     Document Type: Article

References (58)

1. Aguilar F., Harris C.C., Sun T., Hollstein M., and Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264 (1994) 1317-1319
2. Alison M.R., and Lovell M.J. Liver cancer: the role of stem cells. Cell Prolif. 38 (2005) 407-421
3. Artandi S.E., and Depinho R.A. Mice without telomerase: what can they teach us about human cancer?. Nat. Med. 6 (2000) 852-855
4. Bashyam M.D., Bair R., Kim Y.H., Wang P., Hernandez-Boussard T., Karikari C.A., Tibshirani R., Maitra A., and Pollack J.R. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 7 (2005) 556-562
5. Basu S., Totty N.F., Irwin M.S., Sudol M., and Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell 11 (2003) 11-23
6. Block G.D., Locker J., Bowen W.C., Petersen B.E., Katyal S., Strom S.C., Riley T., Howard T.A., and Michalopoulos G.K. Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium. J. Cell Biol. 132 (1996) 1133-1149
7. Chan E.H., Nousiainen M., Chalamalasetty R.B., Schafer A., Nigg E.A., and Sillje H.H. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 24 (2005) 2076-2086
8. Collins C., Volik S., Kowbel D., Ginzinger D., Ylstra B., Cloutier T., Hawkins T., Predki P., Martin C., Wernick M., et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res. 11 (2001) 1034-1042
9. Conze D.B., Albert L., Ferrick D.A., Goeddel D.V., Yeh W.C., Mak T., and Ashwell J.D. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol. Cell. Biol. 25 (2005) 3348-3356
10. Cox C., Bignell G., Greenman C., Stabenau A., Warren W., Stephens P., Davies H., Watt S., Teague J., Edkins S., et al. A survey of homozygous deletions in human cancer genomes. Proc. Natl. Acad. Sci. USA 102 (2005) 4542-4547
11. Crook N.E., Clem R.J., and Miller L.K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. 67 (1993) 2168-2174
12. Dai Z., Zhu W.G., Morrison C.D., Brena R.M., Smiraglia D.J., Raval A., Wu Y.Z., Rush L.J., Ross P., Molina J.R., et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum. Mol. Genet. 12 (2003) 791-801
13. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
14. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., and Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17 (1998) 2215-2223
15. Edgar B.A. From cell structure to transcription: Hippo forges a new path. Cell 124 (2006) 267-273
16. Feitelson M.A., Sun B., Satiroglu Tufan N.L., Liu J., Pan J., and Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 21 (2002) 2593-2604
17. Futreal P.A., Wooster R., and Stratton M.R. Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. Cold Spring Harb. Symp. Quant. Biol. 70 (2005) 1-8
18. Garber K. Human Cancer Genome Project moving forward despite some doubts in community. J. Natl. Cancer Inst. 97 (2005) 1322-1324
19. Goyal L., McCall K., Agapite J., Hartwieg E., and Steller H. Induction of apoptosis by Drosophila reaper, hid and grim through inhibition of IAP function. EMBO J. 19 (2000) 589-597
20. Guo D., Fu T., Nelson J.A., Superina R.A., and Soriano H.E. Liver repopulation after cell transplantation in mice treated with retrorsine and carbon tetrachloride. Transplantation 73 (2002) 1818-1824
21. Hamaratoglu F., Willecke M., Kango-Singh M., Nolo R., Hyun E., Tao C., Jafar-Nejad H., and Halder G. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol. 8 (2006) 27-36
22. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
23. Hu L., Lau S.H., Tzang C.H., Wen J.M., Wang W., Xie D., Huang M., Wang Y., Wu M.C., Huang J.F., et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23 (2004) 298-302
24. Huang J., Wu S., Barrera J., Matthews K., and Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122 (2005) 421-434
25. Imoto I., Yang Z.Q., Pimkhaokham A., Tsuda H., Shimada Y., Imamura M., Ohki M., and Inazawa J. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 61 (2001) 6629-6634
26. Kallioniemi O.P., Kallioniemi A., Sudar D., Rutovitz D., Gray J.W., Waldman F., and Pinkel D. Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors. Semin. Cancer Biol. 4 (1993) 41-46
27. Kim M., Gans J.D., Nogueira C., Wang A., Paik J.-H., Feng B., Brennan C., Hahn W.C., Cordon-Cardo C., Wagner S.N., et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125 (2006) 1269-1281 this issue
28. Lacasse E.C., Baird S., Korneluk R.G., and MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 (1998) 3247-3259
29. Laconi E., Oren R., Mukhopadhyay D.K., Hurston E., Laconi S., Pani P., Dabeva M.D., and Shafritz D.A. Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retrorsine. Am. J. Pathol. 153 (1998) 319-329
30. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., and Lee S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24 (2005) 1477-1480
31. Liston P., Fong W.G., and Korneluk R.G. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22 (2003) 8568-8580
32. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
33. Lowe S.W., Cepero E., and Evan G. Intrinsic tumour suppression. Nature 432 (2004) 307-315
34. Lucito R., Healy J., Alexander J., Reiner A., Esposito D., Chi M., Rodgers L., Brady A., Sebat J., Troge J., et al. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res. 13 (2003) 2291-2305
35. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
36. Ma F., Zhang C., Prasad K.V., Freeman G.J., and Schlossman S.F. Molecular cloning of Porimin, a cell lung cancer to gefitinib cell death. Proc. Natl. Acad. Sci. USA 98 (2001) 9778-9783
37. McClatchey A.I., and Giovannini M. Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev. 19 (2005) 2265-2277
38. Murakami H., Sanderson N.D., Nagy P., Marino P.A., Merlino G., and Thorgeirsson S.S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res. 53 (1993) 1719-1723
39. Narita M., Nunez S., Heard E., Narita M., Lin A.W., Hearn S.A., Spector D.L., Hannon G.J., and Lowe S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113 (2003) 703-716
40. Nitou M., Sugiyama Y., Ishikawa K., and Shiojiri N. Purification of fetal mouse hepatoblasts by magnetic beads coated with monoclonal anti-e-cadherin antibodies and their in vitro culture. Exp. Cell Res. 279 (2002) 330-343
41. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94 (2001) 153-156
42. Peng S.Y., Lai P.L., and Hsu H.C. Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J. Formos. Med. Assoc. 92 (1993) 866-870
43. Salvesen G.S., and Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3 (2002) 401-410
44. Sandgren E.P., Quaife C.J., Pinkert C.A., Palmiter R.D., and Brinster R.L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4 (1989) 715-724
45. Schmitt C.A., Fridman J.S., Yang M., Baranov E., Hoffman R.M., and Lowe S.W. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1 (2002) 289-298
46. Segal E., Friedman N., Kaminski N., Regev A., and Koller D. From signatures to models: understanding cancer using microarrays. Nat. Genet. 37 Suppl (2005) S38-S45
47. Silke J., Kratina T., Chu D., Ekert P.G., Day C.L., Pakusch M., Huang D.C., and Vaux D.L. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc. Natl. Acad. Sci. USA 102 (2005) 16182-16187
48. Snijders A.M., Schmidt B.L., Fridlyand J., Dekker N., Pinkel D., Jordan R.C., and Albertson D.G. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 24 (2005) 4232-4242
49. St John M.A., Tao W., Fei X., Fukumoto R., Carcangiu M.L., Brownstein D.G., Parlow A.F., McGrath J., and Xu T. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat. Genet. 21 (1999) 182-186
50. Strano S., Munarriz E., Rossi M., Castagnoli L., Shaul Y., Sacchi A., Oren M., Sudol M., Cesareni G., and Blandino G. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J. Biol. Chem. 276 (2001) 15164-15173
51. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9 (1994) 2145-2152
52. Suzuki K., Hayashi N., Yamada Y., Yoshihara H., Miyamoto Y., Ito Y., Ito T., Katayama K., Sasaki Y., and Ito A. Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 20 (1994) 1231-1236
53. Takahashi Y., Miyoshi Y., Takahata C., Irahara N., Taguchi T., Tamaki Y., and Noguchi S. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin. Cancer Res. 11 (2005) 1380-1385
54. Tamaskovic R., Bichsel S.J., and Hemmings B.A. NDR family of AGC kinases-essential regulators of the cell cycle and morphogenesis. FEBS Lett. 546 (2003) 73-80
55. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., and Harris C.C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA 91 (1994) 2230-2234
56. Wright C.W., and Duckett C.S. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J. Clin. Invest. 115 (2005) 2673-2678
57. Yagi R., Chen L.F., Shigesada K., Murakami Y., and Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 18 (1999) 2551-2562
58. Zender L., Xue W., Cordon Cardo C., Hannon G.J., Lucito R., Powers S., Flemming P., Spector M.S., and Lowe S.W. Generation and analysis of genetically-defined liver carcinomas derived from bi-potential liver progenitors. Cold Spring Harb. Symp. Quant. Biol. (2006) in press